DRUG FOR INHIBITING LECTIN-LIKE OXIDIZED LDL RECEPTOR AND DRUG FOR PREVENTING ARTERIOSCLEROSIS
申请人:National Cerebral and Cardiovascular Center
公开号:EP2447257A1
公开(公告)日:2012-05-02
A compound having an excellent activity to inhibit a lectin-like oxidized LDL receptor has been identified.
There are provided a drug for inhibiting a lectin-like oxidized LDL receptor characterized by including a trimeric or higher polymeric procyanidin as an active ingredient, which is useful in treating and preventing diseases, in particular, arteriosclerotic diseases, for which a lectin-like oxidized LDL receptor acts as an aggravating factor;
the aforementioned drug for inhibiting a lectin-like oxidized LDL receptor, characterized in that the procyanidin is derived from a plant material selected from the group consisting of apples, grape seeds, peanut seed coats and pine barks; and
a drug for preventing arteriosclerosis including a trimeric or higher polymeric procyanidins as an active ingredient, and characterized by having an activity to inhibit a lectin-like oxidized LDL receptor.
现已发现一种化合物具有抑制凝集素样氧化低密度脂蛋白受体的优异活性。
提供了一种用于抑制凝集素样氧化低密度脂蛋白受体的药物,其特征在于包括三聚或更高聚合原花青素作为活性成分,该药物可用于治疗和预防凝集素样氧化低密度脂蛋白受体作为加重因素的疾病,特别是动脉硬化性疾病;
上述用于抑制凝集素样氧化低密度脂蛋白受体的药物,其特征在于原花青素来自选自苹果、葡萄籽、花生种皮和松树皮组成的植物材料组;以及
一种预防动脉硬化的药物,包括作为活性成分的三聚或更高聚合原花青素,其特征在于具有抑制凝集素样氧化低密度脂蛋白受体的活性。